HomeEXECUTIVES
EXECUTIVES
The medical device news magazine is the latest source for industry scoop. In this article, we take a look at which executives are on the move.
As the medical device industry rapidly expands, so does the need for executive leadership. Recently, several top executives have made moves within the industry. Some have taken new positions at other companies, while others have started their own businesses. Here’s a look at who’s been making headlines lately.
Avania Names MedTech Industry Veteran, Todd M Pope, New Chairman of the Board
Todd M Pope brings 30 years of technology, medical device, and leadership experience across large cap and startup MedTech and was named to TIME Magazine’s 2018 list of 50 Most Influential People in Healthcare.
Soleo Health Chief Executive Officer Drew Walk Named to NHIA Board of Directors
Drew Walk joins a group of seasoned home infusion experts on the NHIA board, an industry governing body. NHIA is the leading industry association providing education, information, advocacy and resources for the nation’s home and alternate site infusion provider community and the manufacturers, suppliers and service companies who support them.
Foster Supply Chain Solutions Hires Brian Savel for Midwest Business Development Representative
Brian Savel brings an excellent and diverse track record of successful sales/business development experience to Foster SCS and his customers and potential customers.
ViroCell Appoints John A Dawson CBE as Chairman of the Board of Directors
John A Dawson said, “I am delighted to join ViroCell’s Board of Directors as its Chairman to help it become a global leader in the cell and gene therapy clinical trials CDMO market. I am impressed by both the quality and experience of ViroCell’s team and the speed with which they have scaled the organisation. Now, with access to state-of-the-art facilities, ViroCell stands ready to begin manufacturing and delivering vectors to clients. What makes ViroCell unique and stand out among other CDMOs is that its team’s track record of designing and manufacturing vectors for clinical trials over twenty years places them among the most knowledgeable and experienced vector teams in the world. The number of partners that have approached ViroCell for their vector needs is a significant leading indicator of future success. I am excited to join the company.”
Axis Research & Technologies Appoints Dr. Mark G. Freeman as Chief Medical Advisor
Axis Research & Technologies notes Dr Freeman has built a strong reputation for excellence with his ability to manage complex conditions including primary and revision surgeries, fractures, and musculoskeletal infections
Dr Jim Lalonde Joins the Board of Directors at Willow
Dr Jim Lalonde has pioneered key advancements in enzyme engineering and biocatalysis that has revolutionized chemical production, protein engineering for food and nutrition, as well as drug discovery and development leading to new routes to pharmaceutical actives behind blockbuster drugs.
Ernesto Pollano Promoted to General Sales Manager, Mexico / LATAM
Ernesto Pollano will lead MicroCare sales and marketing in Mexico and Latin America. He will develop and grow the sales organization, strengthen relationships with distributors and manufacturers representatives, develop key new partnerships to increase revenue across all MicroCare product platforms, and identify strategic opportunities to increase sales in Mexico
Dr Karla Loken Appointed New CMO at FEMSelect Ltd.
Dr Karla Loken joins FEMSelect's executive team at a pivotal time of US expansion and is tasked with helping the company meet its objectives for 2023 and beyond.
Cardiac Dimensions Appoints Angie Swenson VP Clinical Operations
Angie Swenson has spent most of the last 20 years leading clinical trials in the U.S., Europe, Japan and Canada and collaborating on reimbursement strategies for therapies targeting cardiovascular disease developed by leading medtech innovators. Most recently, she served as Vice President, Clinical and Regulatory for HLT, Inc., developer of transcatheter aortic heart valve replacement (TAVR) technology, where for five years she led their early feasibility studies.
